Jeudi du PSCC #17 : Overview of Antibody-Drug Conjugates (ADCs) in clinic & challenges for next generation molecules

Ne manquez pas le prochain Jeudi du PSCC sur le thème : Overview of Antibody-Drug Conjugates (ADCs) in clinic & challenges for next generation molecules

avec nos speakers : 

• Barbara Pistilli, MD (Medical oncologist specializing in breast cancer)

• Olivier Rixe (Global Head of Early Clinical Development, Daiichi Sankyo) 

• Julien Elric (Senior Principal at Jeito Capital)

  
  

Barbara Pistilli, MD is the chair of the breast cancer unit at Gustave Roussy since March 2021. The clinical activity of Breast Cancer Group encloses around 2000 new patients and about 300 inclusions in clinical trials, yearly. The goal of the group is to provide groundbreaking and patient-centered strategies that cover all steps from breast cancer prevention to development of innovative treatment strategies and survivorship care. The scientific strategy is driven by the integration between translational and clinical sciences in a several large comprehensive programs, where knowledge in biology drives clinical development and patient samples feed translational research. She also leads a large international program, OASIS, funded by European Union’s Horizon Europe research,  focusing on identification of predictors of response and identification of companion diagnostics to antibody drug conjugates. She is the Principal Investigator of several national and international phase II and phase III studies in early and advanced breast cancer.

Olivier Rixe, MD, PhD, is an internationally recognized medical oncologist in the field of developmental therapeutics. While working as an oncologist, he has had nearly 300 publications. He has held a senior position in academia for the past 25 years where he has conducted early clinical trials in patients with resistant tumors, including many translational studies, testing new therapeutic strategies with chemotherapy, gene therapy, targeted therapy and immunotherapy. He served as a senior investigator in the Phase 1 Unit at Gustave Roussy Institute in Villejuif, France. Dr. Rixe was appointed Professor of Medical Oncology in 2003 at Pierre and Marie Curie University (Paris 6). In 2008, Dr. Rixe joined the Medicine Oncology Branch at the NCI in Bethesda, MD as a staff clinician. In 2009, Dr. Rixe came to the University of Cincinnati (UC) as a Professor of Medicine and the John and Gladys Strauss Chair in cancer research and assumed the position of both Director of the Experimental Therapeutics Program and Research Director of the UC Brain Tumor Center. In 2014, he joined the NCI-designated Cancer Center at University of New Mexico, as Cancer Center Associate Director and Head of the Experimental Therapeutics Unit.

He is Vice President at Daiichi Sankyo, NJ for early drug development, since April 2022.

Julien Elric is a Senior Principal at Jeito Capital, bringing strong experience in deal sourcing, portfolio support, and healthcare investment. He joined Jeito in September 2021 as an Associate (2021) before being promoted Senior Associate in 2023 and Principal in early 2024. Within Jeito’s investment team, Julien has contributed to financing efforts and clinical development strategies across the portfolio. Before joining Jeito, Julien led the startup incubator iPEPS at the Paris Brain Institute, where he helped establish it as a key hub for life sciences innovation in France. He supported early-stage biotechs and medtechs in their growth (fund raising, partnerships) and advised major pharmaceutical companies (Pfizer, Janssen, Astra Zeneca, etc.) on corporate–startup collaborations. Earlier in his career, he was responsible for business development and industrial partnerships at Institut Curie. Julien holds a PhD in Cell Biology from Institut Pasteur and is a graduate of INSEAD Business School.

On-site & online